STAGE IIIA BLADDER CANCER AJCC V8
Clinical trials for STAGE IIIA BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIA BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a rheumatoid arthritis drug tame Immunotherapy's side effects?
Disease control OngoingThis study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…
Matched conditions: STAGE IIIA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
Immunotherapy boost for bladder cancer: could adding atezolizumab to standard treatment be a Game-Changer?
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with muscle-invasive bladder cancer live longer without their cancer returning or needing bladder removal. About 475 adults with localized disease are participating…
Matched conditions: STAGE IIIA BLADDER CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Bladder cancer Survivors' quality of life under the microscope
Knowledge-focused OngoingThis study follows 204 people with bladder cancer to see how their treatment (surgery or radiation) affects their daily life. Participants fill out surveys about their physical function, pain, fatigue, mood, and social activities. The goal is to understand which treatments have t…
Matched conditions: STAGE IIIA BLADDER CANCER AJCC V8
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:08 UTC
-
Can a simple test predict who will respond to immunotherapy?
Knowledge-focused OngoingThis study looks at whether certain gene mutations (ARID1A and KDM6A) and a protein called CXCL13 in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Only 6 participants with these specific gene changes…
Matched conditions: STAGE IIIA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:08 UTC